AU2021255809B2 - Bi- and monocyclic nucleoside analogs for treatment of hepatitis E - Google Patents

Bi- and monocyclic nucleoside analogs for treatment of hepatitis E

Info

Publication number
AU2021255809B2
AU2021255809B2 AU2021255809A AU2021255809A AU2021255809B2 AU 2021255809 B2 AU2021255809 B2 AU 2021255809B2 AU 2021255809 A AU2021255809 A AU 2021255809A AU 2021255809 A AU2021255809 A AU 2021255809A AU 2021255809 B2 AU2021255809 B2 AU 2021255809B2
Authority
AU
Australia
Prior art keywords
compound
group
pharmaceutically acceptable
compounds
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021255809A
Other languages
English (en)
Other versions
AU2021255809A1 (en
Inventor
Yannick DEBING
Tim Hugo Maria Jonckers
Frederik PAUWELS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of AU2021255809A1 publication Critical patent/AU2021255809A1/en
Application granted granted Critical
Publication of AU2021255809B2 publication Critical patent/AU2021255809B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2021255809A 2020-04-14 2021-04-13 Bi- and monocyclic nucleoside analogs for treatment of hepatitis E Active AU2021255809B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20169480 2020-04-14
EP20169480.9 2020-04-14
PCT/EP2021/059504 WO2021209419A1 (en) 2020-04-14 2021-04-13 Bi- and monocyclic nucleoside analogs for treatment of hepatitis e

Publications (2)

Publication Number Publication Date
AU2021255809A1 AU2021255809A1 (en) 2022-12-15
AU2021255809B2 true AU2021255809B2 (en) 2026-08-06

Family

ID=70289599

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021255809A Active AU2021255809B2 (en) 2020-04-14 2021-04-13 Bi- and monocyclic nucleoside analogs for treatment of hepatitis E

Country Status (15)

Country Link
EP (1) EP4135715B1 (cg-RX-API-DMAC7.html)
JP (2) JP2023522615A (cg-RX-API-DMAC7.html)
KR (1) KR20230002592A (cg-RX-API-DMAC7.html)
CN (1) CN115515603A (cg-RX-API-DMAC7.html)
AR (1) AR121836A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021255809B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022020825A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174790A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002804A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982564T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022012904A (cg-RX-API-DMAC7.html)
PE (1) PE20230386A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552679A1 (cg-RX-API-DMAC7.html)
UY (1) UY39172A (cg-RX-API-DMAC7.html)
WO (1) WO2021209419A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024086592A2 (en) * 2022-10-17 2024-04-25 Emory Unversity 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2025014360A1 (en) * 2023-07-07 2025-01-16 Erasmus University Medical Center Rotterdam Guanosine nucleotide analogs for use in preventing and/or treating hepatitis e virus infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150366888A1 (en) * 2014-06-24 2015-12-24 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2952714T3 (es) * 2013-06-26 2023-11-03 Janssen Pharmaceuticals Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
SG11201610597QA (en) * 2014-06-24 2017-01-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2017210438A1 (en) * 2016-06-03 2017-12-07 Gilead Pharmasset Llc Methods of treating hepatitis e viral infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150366888A1 (en) * 2014-06-24 2015-12-24 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Also Published As

Publication number Publication date
CA3174790A1 (en) 2021-10-21
US20230310481A1 (en) 2023-10-05
EP4135715A1 (en) 2023-02-22
CL2022002804A1 (es) 2023-03-31
CN115515603A (zh) 2022-12-23
PH12022552679A1 (en) 2024-04-22
BR112022020825A2 (pt) 2022-11-29
EP4135715B1 (en) 2024-05-08
ES2982564T3 (es) 2024-10-16
MX2022012904A (es) 2023-01-24
AU2021255809A1 (en) 2022-12-15
PE20230386A1 (es) 2023-03-06
UY39172A (es) 2021-10-29
EP4135715C0 (en) 2024-05-08
WO2021209419A1 (en) 2021-10-21
AR121836A1 (es) 2022-07-13
KR20230002592A (ko) 2023-01-05
JP2023522615A (ja) 2023-05-31
JP2026120528A (ja) 2026-07-22